n-3脂肪酸补充剂在老年心肌梗死后患者中的随机对照试验
OMEMI试验将1027例70-82岁近期急性心肌梗死患者随机分配至每日1.8g n-3多不饱和脂肪酸或安慰剂组,随访2年。主要复合终点(非致死性心梗、非计划血运重建、卒中、全因死亡、心衰住院)在n-3组与安慰剂组分别为21.4%与20.0%(HR 1.08, 95%CI 0.82-1.41, P=0.60),未观察到临床事件减少。
要点
- 老年心梗后患者每日补充1.8g n-3多不饱和脂肪酸未降低2年主要心血管复合终点风险。
- 次要终点新发房颤在n-3组有升高趋势(7.2% vs 4.0%, P=0.06),但未达统计学显著性。
- 大出血发生率两组相似(10.7% vs 11.0%, P=0.87),安全性无显著差异。
核心结论
- 在近期急性心肌梗死的老年患者中,每日补充1.8g n-3多不饱和脂肪酸2年未能减少临床心血管事件。
研究设计与样本
- OMEMI试验为研究者发起的多中心随机对照试验,共随机1027例70-82岁近期(2-8周)急性心肌梗死患者,每日补充1.8g n-3多不饱和脂肪酸(930mg EPA和660mg DHA)或安慰剂(玉米油),随访2年。
主要发现
- 主要复合终点(非致死性心梗、非计划血运重建、卒中、全因死亡、心衰住院)在n-3组发生108例(21.4%),安慰剂组102例(20.0%),HR 1.08(95%CI 0.82-1.41),P=0.60。
- 次要终点新发房颤在n-3组28例(7.2%),安慰剂组15例(4.0%),HR 1.84(95%CI 0.98-3.45),P=0.06。
- 大出血在n-3组54例(10.7%),安慰剂组56例(11.0%),P=0.87。
- 依从性生物标志物:n-3组EPA和DHA中位变化分别为+87%和+16%,安慰剂组为-13%和-8%。
- 符合方案分析(n=893)结果相似。
关键数值与推荐
- 入组年龄70-82岁,近期(2-8周)急性心肌梗死,每日补充1.8g n-3多不饱和脂肪酸(含930mg EPA和660mg DHA)。
- 主要终点为2年非致死性心梗、非计划血运重建、卒中、全因死亡、心衰住院的复合终点。
临床怎么用
- 对于近期急性心肌梗死的老年患者,常规补充1.8g n-3多不饱和脂肪酸未显示心血管事件减少的获益,不支持以此作为二级预防常规措施。
局限性
- 随访时间仅2年,可能不足以观察到长期效应。
- 研究人群为70-82岁老年患者,结果不能外推至其他年龄段。
- 开放标签设计可能影响行为因素,但依赖盲法终点评估和生物标志物依从性检测部分缓解。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High intake of marine n-3 polyunsaturated fatty acids (PUFA) has been associated with reduced risk of cardiovascular events; however, this has not been confirmed in patients with a recent acute myocardial infarction (AMI). Elderly patients are at particularly increased cardiovascular risk after myocardial infarction, but few trials address this group specifically. Omega-3 fatty acids hold the potential to reduce cardiovascular events with limited adverse effects in this vulnerable group. The hypothesis was that daily addition of 1.8g n-3 PUFA to standard of care secondary prophylaxis in elderly patients who have survived an AMI would reduce the risk of subsequent cardiovascular events during 2 years follow-up. METHODS: The OMEMI trial (Omega-3 Fatty acids in Elderly with Myocardial Infarction) is an investigator-initiated, multicenter, randomized clinical trial adding 1.8 g n-3 PUFA (930 mg eicosapentaenoic acid and 660 mg docosohexaenoic acid) versus placebo (corn oil) daily to standard of care in patients aged 70 to 82 years with recent (2-8 weeks) AMI. The primary endpoint was a composite of nonfatal AMI, unscheduled revascularization, stroke, all-cause death, heart failure hospitalization after 2 years. The secondary outcome was new atrial fibrillation. The safety outcome was major bleeding. Serum fatty acids were measured as biomarkers of adherence. RESULTS: In total, 1027 patients were randomized. Follow-up data were available for 1014 patients who were included in the intention-to-treat analysis. Mean±SD age was 75±3.6 years, 294 (29%) were female, and mean triglycerides were 111.4±61.9 mg/dL. The primary endpoint occurred in 108 (21.4%) patients on n-3 PUFA versus 102 (20.0%) on placebo (hazard ratio, 1.08 [95% CI, 0.82-1.41]; P=0.60). The secondary endpoint occurred in 28 (7.2%) patients on n-3 PUFA versus 15 (4.0%) on placebo (1.84 [0.98-3.45]; P=0.06). Median changes in eicosapentaenoic acid and docosahexaenoic acid were +87% and +16% for n-3 PUFA versus -13% and -8% for placebo. Major bleeding occurred in 54 (10.7%) and 56 (11.0%) in the n-3 PUFA and placebo groups, respectively (P=0.87). Similar results were found in per-protocol analysis (n=893). CONCLUSIONS: We could not detect reduction in clinical events in our elderly patients with recent AMI who were treated with 1.8 g n-3 PUFAs daily for 2 years. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01841944.
引用
- Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial. Circulation. 2020. PMID: 33191772. doi:10.1161/CIRCULATIONAHA.120.052209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。